Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Li, Qin ^a   Yan, Han ^a   Liu, Wenting ^a   Zhen, Hongchao ^a   Yang, Yifan ^a   Cao, Bangwei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; KAPLAN MEIER METHOD; META ANALYSIS (TOPIC); METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; META ANALYSIS; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84905650613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104346     Document Type: Article

References (33)

1. Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, et al. (2009) Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol 2: 13.
2. Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, et al. (2007) Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 110: 525-533. (Pubitemid 47106140)
3. Burris HR, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413. (Pubitemid 27251144)
4. Choi JH, Oh SY, Kwon HC, Kim JH, Lee JH, et al. (2008) Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis. Cancer Res Treat 40: 22-26.
5. Xie DR, Yang Q, Chen DL, Jiang ZM, Bi ZF, et al. (2010) Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol 40: 432-441.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966. (Pubitemid 46972777)
7. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703.
8. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, et al. (2013) Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 49: 593-603.
9. Hu J, Zhao G, Wang HX, Tang L, Xu YC, et al. (2011) A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 4: 11.
10. Sun C, Ansari D, Andersson R, Wu DQ (2012) Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 18: 4944-4958.
11. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, et al. (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20: 3130-3136. (Pubitemid 34791103)
12. Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, et al. (2006) Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 94: 1107-1115.
13. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, et al. (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20: 160-164. (Pubitemid 34032607)
14. Saif MW, Syrigos KN, Katirtzoglou NA (2009) S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 18: 335-348.
15. Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39: 2-15.
16. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, et al. (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94: 1575-1579. (Pubitemid 43924916)
17. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
18. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
19. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
20. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
21. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, et al. (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275. (Pubitemid 34831525)
22. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, et al. (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14: 97-104. (Pubitemid 36150266)
23. Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, et al. (2005) Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 93: 185-189. (Pubitemid 41133204)
24. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, et al. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212-2217. (Pubitemid 46954645)
25. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, et al. (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518.
26. Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, et al. (2012) A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 106: 1934-1939.
27. Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, et al. (2012) Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 69: 1197-1204.
28. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, et al. (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31: 1640-1648.
29. Xie DR, Liang HL, Wang Y, Guo SS, Yang Q (2006) Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 12: 6973-6981. (Pubitemid 44834888)
30. Ling W, Fan J, Ma Y, Ma Y, Wang H (2011) Capecitabine-based chemotherapy for metastatic colorectal cancer. J Cancer Res Clin Oncol 137: 927-938.
31. Hubner RA, Worsnop F, Cunningham D, Chau I (2013) Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer. Pancreas 42: 511-515.
32. Choi JG, Seo JH, Oh SC, Choi CW, Kim JS (2012) A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Res Treat 44: 127-132.
33. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, et al. (2013) Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 31: 23-29.